What is Larimar Therapeutics Inc (LRMR) stock price today?

Larimar Therapeutics Inc (LRMR) currently trades at $4.06 per share. The stock has a market capitalization of $461.24M and a P/E ratio of —x.

Is LRMR stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Larimar Therapeutics Inc has a Smart Value Score of 23/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -0.08.

Is Larimar Therapeutics Inc financially healthy?

Larimar Therapeutics Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -0.08 places it in the distress.

LRMR

Larimar Therapeutics Inc

NASDAQ: LRMR · HEALTHCARE · BIOTECHNOLOGY

$4.06

-6.45% today

Updated 2026-04-30

Market cap

$461.24M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.27

Dividend yield

—

52W range

$2 – $6

Volume

5.0M

Market cap

$461.24M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.27

Dividend yield

—

52W range

$2 – $6

Volume

5.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-0.1

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$16.70

+311.33%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.03x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -0.08 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-38.53M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-34.18M	$-36.95M	$-80.60M	$-165.67M	$-62.50M
EPS	—	—	—	—	$-2.27
Free cash flow	$-27.67M	$-33.62M	$-71.28M	$-113.29M	$-38.53M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-02-27	THOMAS, FRANK E	Buy	5,000	$5.00
2026-02-27	SHERMAN, JEFFREY W	Buy	5,000	$5.00
2026-02-27	HAMILTON, THOMAS EDWARD	Buy	100,000	$5.00

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LRMR	$461.24M	23	4.3	3.0	5.0	6.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Larimar Therapeutics Inc trades at $4.06. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -0.08, it sits in the distress.

Frequently asked questions

What is Larimar Therapeutics Inc's stock price?

Larimar Therapeutics Inc (LRMR) trades at $4.06.

Is Larimar Therapeutics Inc overvalued?

Smart Value Score 23/100 (Grade F, Strong Sell).

What is the price target of Larimar Therapeutics Inc (LRMR)?

The analyst target price is $16.70, representing +311.3% upside from the current price of $4.06.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-0.08 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

larimartx.com

Quick metrics

P/S ratio—

ROE-132.60%

Beta1.02

50D MA$4.63

200D MA$3.98

Shares out0.10B

Float0.05B

Short ratio—

Avg volume5.0M

Performance

1 week-2.84%

1 month-3.90%

3 months+20.98%

YTD+16.54%

1 year—

3 years—

5 years—

Compare

LRMR vs LLY →LRMR vs JNJ →LRMR vs ABBV →Stock screener →